Partnerships & Mergers

Ustekinumab is a monoclonal antibody used to treat certain immune-mediated inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Under the agreement, ADSCC will contribute its cell therapy development and manufacturing infrastructure, while Miltenyi will provide scientific and technical support for its proprietary viral vector and anti-CD19 chimeric antigen receptor technologies.

Mediclinic Middle East is exploring how ambient AI can capture relevant information from clinician-patient conversations and convert it into structured clinical notes for review, reducing the need for manual documentation during consultations.

The women’s health and fertility portfolio will cover several stages of reproductive health, including fertility, pregnancy and childbirth.

The partnership was formalized through a memorandum of understanding (MoU) at the Abu Dhabi Future Health Summit 2026.

The proposed partnership will combine Burjeel’s oncology services and clinical research infrastructure with Avatrial’s artificial intelligence (AI) and multi-omics technologies.

The agreement also includes US$35 million in preclinical milestone payments, with additional development and commercial milestones bringing the total potential deal value to nearly US$1.2 billion.

The facility includes ISO Class 8 cleanrooms, a secondary packaging area, quality control laboratories and a microbiology laboratory equipped for sterility testing.

Under the agreement, AstraZeneca will pay US$40 million upfront, with an additional US$1.46 billion available in development and commercial milestone payments.

The campaign combines Aster Clinics’ healthcare services with Nezo Salt’s consumer and retail network to encourage women to seek medical advice and prioritise breast health.